CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
CRC9 (NCT04068103), Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA), has been centrally activated.
This past week the central office has continued to support CCTG network activities including addressing impacts of COVID-19.
CCTG regulatory/ethics compliance and trial teams rolled out COVID-19 addenda for all trials. These addenda have been added to all CCTG trial pages to support sites and trial teams in our network. We are also incorporating an EDC form for the collection of COVID-19 information for designated trials.
As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials.
People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic.
Dear Colleagues:
Across the country, people, patients and health care providers have been directly impacted by preparations and managing the effects of the COVID pandemic. We have all worked to implement measures to reduce risk of infection even as we have tried to maintain the best care for patients with cancer.
For CCTG, we have defined the following priorities
The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study.
The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
CCTG and its scope of research has been deemed an essential service by Queen’s University and we continue to be operational for our sites and trial patients. Given the critical nature of our research, we continue to monitor our activities and how trial adjustments can be made to ensure that patients can be managed on protocols.
The CCTG Operations and Statistics Centre has successfully completed the transition to a remote work environment with a small number of support staff in the offices.
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19).
